Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 1998, p. 2985-2988, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Purification and Characterization of Virginiamycin
M1 Reductase from Streptomyces
virginiae
Naoyoshi
Suzuki,
Chang-Kwon
Lee,
Takuya
Nihira,* and
Yasuhiro
Yamada
Department of Biotechnology, Graduate School
of Engineering, Osaka University, Suita, Osaka 565-0871, Japan
Received 18 June 1998/Returned for modification 17 August
1998/Accepted 1 September 1998
 |
ABSTRACT |
Virginiamycin M1 (VM1), produced by
Streptomyces virginiae, is a polyunsaturated macrocyclic
lactone antibiotic belonging to the virginiamycin A group.
S. virginiae possesses an activity which stereospecifically
reduces a 16-carbonyl group of VM1, resulting in
antibiotically inactive 16R-dihydroVM1. The
corresponding VM1 reductase was purified to
homogeneity from crude extracts of S. virginiae in five
steps, with 5,650-fold purification and 23% overall yield. The
N-terminal amino acid sequence was determined to be MAIKLVIA. The
purified enzyme showed an apparent Mr of 73,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and an
Mr of 280,000 by native molecular sieve
high-performance liquid chromatography, indicating the tetrameric
nature of the native enzyme. NADPH served as a coenzyme for the
reduction, with a Km value of 0.13 mM, but NADH
did not support the reaction, even at a concentration of 5 mM,
indicating the NADPH-specific nature of the enzyme. The
Km for VM1 was determined to be 1.5 mM in the presence of 2 mM NADPH. In the reverse reaction, only
16R-dihydroVM1, not the 16S-epimer,
served as a substrate, with a less than 0.1% overall
reaction rate compared to that of the forward reaction, confirming
that the VM1 reductase participates solely in
VM1 inactivation in vivo.
 |
INTRODUCTION |
The antibiotic virginiamycin,
produced by Streptomyces virginiae, is a member of the
virginiamycin family (alternatively designated as the streptogramin
family or the mikamycin family) (2). The characteristic
feature of the family is that each member is produced as a mixture of
two structurally different compounds exhibiting a synergistic
antibacterial activity. They belong to one of the two following
distinct groups: type A, exemplified by virginiamycin M1 (VM1), corresponding to polyunsaturated
macrocyclic peptolides (Fig. 1); and type
B, exemplified by virginiamycin S, corresponding to branched
cyclic hexadepsipeptide. Each compound reversibly blocks
protein synthesis and displays only bacteriostatic activity. However, in combination, they demonstrate a synergistic bactericidal activity at much lower concentrations. The virginiamycin family, which
has been known for more than 30 years (3), has been used successfully as a performance promoter in animal husbandry
(1).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Structures of VM1, virginiamycin S, and a VB
and conversion of VM1 to
16R-dihydroVM1. Me, methyl.
|
|
Studies of antibiotic inactivation by producer microorganisms are
important for understanding the producer's defense mechanism against
antibiotics and providing clues for locating the gene clusters
necessary for antibiotic biosynthesis. However, despite the long
history of virginiamycin production by S. virginiae, no
enzymatic study of the inactivation of virginiamycin has been reported.
Previously, we have confirmed that S. virginiae
inactivates VM1 by reducing its 16-carbonyl group,
stereospecifically forming 16R-dihydroVM1 (Fig.
1) (8), while leaving virginiamycin S intact. In this study,
we have purified the corresponding enzyme, VM1 reductase,
5,650-fold from the crude cell extract of S. virginiae and characterized it.
 |
MATERIALS AND METHODS |
Bacterial strains and cultivation conditions.
S.
virginiae MAFF 10-06014 (National Food Research Institute,
Ministry of Agriculture, Forestry and Fisheries, Tsukuba, Japan) was
used throughout this study. It was grown at 28°C for 40 h as
previously described (4, 5).
Chemicals.
To obtain pure VM1, fodder additive
STAFAC 500 (0.5 g; Smith Kline-RIT, Rixensart, Belgium) was suspended
in 100 ml of acetonitrile, and the suspension was incubated for 16 h at 120 rpm and 30°C. After filtration with a glass filter
(5-µm-pore diameter; Whatman), the filtrate was evaporated to
dryness, and VM1 in the residue was purified by
C18 reverse-phase high-performance liquid chromatography (HPLC) (Cosmosil 5C18-AR; 10 by 250 mm; Nacalai Tesque, Kyoto, Japan)
with 50% CH3CN in water as the mobile phase at room
temperature and at a flow rate of 3 ml/min with detection at 305 nm.
VM1 and virginiamycin S were eluted at 11.0 and 18.0 min,
respectively. Authentic 16R-dihydroVM1 and its
16S-epimer were prepared by chemical reduction with
NaBH4 and purified by C18 reverse-phase HPLC as described previously (8). Their identity was confirmed by
mass spectrometry and 600-MHz 1H-nuclear magnetic resonance spectrometry.
Assay of VM1 reductase activity.
The
VM1 reductase activity during the purification was
routinely monitored by the addition of 1 µl of VM1 (10 mg/ml in ethanol) to the reaction mixture containing an appropriate
amount of enzyme and 2 mM NADPH in 0.05 M triethanolamine-HCl (TEA) (pH
7.5) for a total volume of 100 µl. For measuring total activity, pH
optimum, and Km for NADPH, the concentration of
VM1 was raised to 9.1 mM (5-µl addition of a 100-mg/ml
VM1 solution) to ensure maximum activity. Due to the
relatively nonpolar nature of VM1, 9.1 mM is nearly a
saturating concentration in the buffer. The activities in 0.05 M
potassium phosphate (pH 7.5), 0.05 M Tris-HCl (pH 7.5), and 0.05 M
3-(N-morpholine)propanesulfonic acid-KOH (pH 7.5) were 72, 123, and 91%, respectively, relative to that in 0.05M TEA (pH 7.5).
Because Tris-HCl buffer gave high background
A210 during HPLC detection, TEA was selected as
the buffer. Incubation was carried out at 28°C and at a rate of 40 strokes per min in a reciprocating water bath. At appropriate times,
the reaction was stopped by the addition of 400 µl of ethanol, and
denatured proteins were removed by centrifugation (11,000 × g, 5 min). 16R-DihydroVM1 in the
supernatant was measured by C18 reverse-phase HPLC
(Cosmosil 5C18 column; 4.6 by 250 mm, detection at 210 nm, flow rate at 1.0 ml/min, isocratic elution with 40% CH3CN in water)
with authentic 16R-dihydroVM1 as a standard. The
elution times for VM1 and
16R-dihydroVM1 were 5.8 and 9.5 min,
respectively. One unit of enzyme activity is defined as the amount of
enzyme necessary to produce 1 µmol of
16R-dihydroVM1 per min at 28°C.
Protein content was determined with a Bio-Rad protein assay kit, unless
otherwise stated, with bovine serum albumin as a
standard.
Purification of VM1 reductase.
All of the
purification procedures were carried out at 0 to 4°C unless otherwise indicated.
(i) Step 1.
Preparation of cell-free extract. In step 1, cells (100 g [wet weight]) from 8 liters of culture were suspended in
500 ml of 0.05 M TEA (pH 7.5) and disrupted by sonication. Cell debris was removed by centrifugation at 6,000 × g for 20 min.
(ii) Step 2. Ammonium sulfate fractionation.
To the
supernatant from step 1, solid ammonium sulfate was added with gentle
stirring to attain 60% saturation while keeping the pH at 7.0. After
standing overnight, the precipitate was collected by centrifugation at
12,000 × g for 20 min and dissolved in 200 ml of 0.02 M TEA (pH 7.0). The solution was dialyzed against two changes of the
same buffer (5 liters) to remove the ammonium sulfate.
(iii) Step 3. DEAE-Sephacel chromatography.
The dialyzed
solution from step 2 was applied to a DEAE-Sephacel column (4.5 by 65 cm) previously equilibrated with 0.02 M TEA (pH 7.0). After being
washed with 2 liters of the same buffer, the protein was successively
eluted with 3 liters of 0.02 M TEA (pH 7.0) containing 0.1 M KCl, 5 liters of 0.02 M TEA (pH 7.0) containing 0.2 M KCl, and finally 3.3 liters of 0.02 M TEA (pH 7.0) containing 0.3 M KCl. The column was
eluted at a flow rate of 340 ml/h, and 18-ml fractions were collected.
VM1 reductase activity was eluted at 0.2 M KCl, and
fractions 65 to 120 were pooled and concentrated by ultrafiltration
(UK-20; Advantech Toyo).
(iv) Step 4. Gel filtration on Sepharose CL-6B column.
The
concentrated solution from step 3 (30 ml) was applied to a Sepharose
CL-6B column (5.5 by 65 cm), preequilibrated with 0.05 M TEA (pH 7.0)
containing 0.3 M KCl, and eluted with the same buffer in fractions of
10 ml at a flow rate of 340 ml/h. Active fractions (fractions 78 to
105) were pooled and concentrated to 50 ml by ultrafiltration.
(v) Step 5. Affinity chromatography on a HiTrap Blue column.
The concentrated solution from step 4 was purified in aliquots of 2 ml
(7.5 mg protein) per run on a HiTrap Blue column (1.0 by 3.0 cm;
Pharmacia LKB) with a linear gradient of NADPH concentration from 0 to
10 mM (0.5 mM/min) in 0.05 M TEA (pH 7.0) containing 0.1 M KCl at a
flow rate of 0.5 ml/min. Protein in the eluate was monitored with a
fluorescence detector (excitation, 280 nm; emission, 340 nm; model
FP-210, Japan Spectroscopic Co., Ltd.). VM1 reductase
activity appeared at around 26 min.
The samples' purity at each purification step was monitored by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
on
a ready-made 4 to 20% gradient gel (Daiichi Pure Chemicals
Co., Ltd.)
with a mini-gel apparatus. Proteins in the gel were
detected by a
silver stain kit (Wako Pure Chemicals) according
to the manufacturer's
protocol. Marker proteins were obtained
from Pharmacia
LKB.
Molecular mass determination of the VM1
reductase.
Purified sample was injected into a molecular sieve
HPLC column (TSK G3000 SWXL; Mr,
500,000; Toso Manufacturing Co., Ltd.), and eluted with 0.1 M
potassium phosphate buffer (pH 7.0) containing 0.2 M NaCl at a flow
rate of 0.5 ml/min. Fractions were collected every 15 s and
assayed for VM1 reductase. The calibration curve was made
from the elution positions of HPLC marker proteins (rabbit muscle
phosphorylase b, Mr, 94,000; bovine serum
albumin, Mr, 67,000; egg ovalbumin,
Mr, 43,000) purchased from Oriental Yeast Co., Ltd.
N-terminal amino acid sequencing.
The N-terminal amino acid
sequence of purified enzyme was analyzed with an automated protein
sequencer (Applied Biosystems 476A protein sequencer). The N-terminal
amino acid sequence was compared to other protein sequences in the
SwissProt, PIR, and PRF databases, but no significant homology was found.
 |
RESULTS AND DISCUSSION |
Purification of VM1 reductase.
To characterize an
enzyme that catalyzes the reduction of the 16-carbonyl group in
VM1, we first had to establish a sensitive assay procedure,
because preliminary experiments indicated that VM1
reductase activity in S. virginiae is very weak, with
an activity of only several microunits per milligram of protein. This
low level of activity prevented us from using conventional assays monitoring the VM1-dependent decay of NADPH or NADH. We
have developed an easy but sensitive assay (detection limit of 1.6 µU
or 0.05 µg of 16R-dihydroVM1 per h) based on
the separation and detection of 16R-dihydroVM1
by C18 reverse-phase HPLC as described in Materials and
Methods. Under the assay conditions, the enzyme reaction proceeded linearly for up to 6 h, as shown in Fig.
2A. Similarly, the practical pH optimum
was determined to be at around 7.5 to 7.8 (Fig. 2B), although the
instability and quick degradation of both VM1 and 16R-dihydroVM1 under acidic conditions could be
the reason for the low activity at a pH lower than 7.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Dependence of VM1 reductase activity on
reaction time (A) and pH (B). (A) The reaction was performed for the
indicated time in the presence of 5 mM NADPH and 2 mM VM1
in 0.05 M TEA-HCl (pH 7.5). (B) The reaction was performed in 0.1 M
TEA-HCl at the indicated pH in the presence of 2 mM NADPH. The pH after
the reaction was confirmed to be the same as that before the
reaction.
|
|
During cultivation of
S. virginiae, the VM
1
reductase activity was not detected in the culture broth (less than 0.2 µU/ml),
while that in the mycelia increased with increasing cell mass
and reached a plateau after 32 h of cultivation in parallel with
the cessation of growth (Fig.
3). These
characteristics suggest
that the enzyme is intracellular and is
produced constitutively,
although we cannot exclude the
possibility that some of the medium
component might be the inducer of
the enzyme.
S. virginiae possesses
a type of
Streptomyces hormones called virginiae butanolides (VBs)
which trigger virginiamycin production at nanomolar concentrations
(
7,
9,
10). Under our cultivation conditions, the production
of VB starts at 11 h of cultivation, which in turn induced
virginiamycin
production with antibiotics first detected at 12.5 h
of cultivation
(
6). Because the VM
1 reductase
activity was already present
in the 9-h mycelia when neither VB
nor virginiamycin was present
(Fig.
3) and the external addition of VB
did not increase the
amount of the enzyme activity (our
unpublished data), VM
1 reductase
seems to be produced
constitutively, irrespective of VB or virginiamycin.
To ensure the
maximum amount of enzyme activity, mycelia harvested
at 40 h
were selected as the source of the enzyme.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Time course of VM1 reductase activity in the
mycelia of S. virginiae. At the indicated time, a
500-ml culture was harvested. After sonication to disrupt cells,
VM1 reductase activity in the crude cell extract was
measured as described in Materials and Methods. Growth ( ) is
expressed as grams (wet weight) of cells per liter of culture.
VM1 reductase activity ( ) is expressed as microunits per
milligram of protein.
|
|
Starting from 100 g of 40-h mycelia, 0 to 60% ammonium-sulfate
precipitation, DEAE-Sephacel ion-exchange chromatography,
Sepharose
CL-6B gel-filtration chromatography, and, finally,
affinity chromatography
on a HiTrap Blue column (Fig.
4A) gave a single band of protein
(Fig.
4B). Affinity chromatography with the group-specific resin
was very
efficient, giving a more than 600-fold increase in enzyme
specific
activity (Table
1). It was so efficient
that no protein
peak was detected for the active fractions by means of
the fluorescence
detector. The protein content of the active fraction
was later
determined by reverse-phase HPLC on a C
8 column
with detection
at 210 nm with bovine serum albumin as a standard.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Affinity chromatography HPLC of VM1
reductase on a HiTrap Blue column (A) and purity analysis of the sample
by SDS-PAGE (B). (A) VM1 reductase activity ( ). A
typical elution profile with a 400-µl injection of the concentrate
from step 3 was demonstrated. The gradient profile of NADPH
concentration is indicated by a broken line. The protein concentration
in the eluate was monitored by fluorescence (excitation, 280 nm;
emission, 340 nm) (solid line). (B) Lane 1, purified enzyme (0.2 µg);
lane 2, molecular mass standards. Numbers on the right indicate the
size of standard proteins in kilodaltons.
|
|
Characterization of VM1 reductase.
The molecular
mass of the enzyme under native conditions was determined to
be 280,000 Da by gel filtration on a G3000SWXL HPLC
column according to the elution position of the enzyme activity (data
not shown). With the molecular mass of 73,000 Da by SDS-PAGE, VM1 reductase under native conditions is concluded to be a homotetramer.
The purified enzyme was analyzed for the amino acid
sequence with an automated protein sequencer. Its N-terminal
sequence
was Met-Ala-Ile-Lys-Leu-Val-Ile-Ala. Only one amino
acid was detected
for each sequencing cycle, which further confirmed
the purity
of the
enzyme.
To characterize its coenzyme specificity, the purified enzyme was
assayed in the presence of 5 mM NADH or NADPH. No activity
was detected
with 5 mM NADH, while very clear activity was observed
with NADPH,
indicating that VM
1 reductase was specific to NADPH.
A
conventional double reciprocal plot determined the
Km for NADPH
to be 0.13 mM in the presence of
9.1 mM VM
1. Similarly, the
Km values
for VM
1 and
Vmax were determined to
be 1.50 mM and 265
mU/mg of protein in the presence of 2 mM
NADPH.
VM
1 reductase catalyzes reduction of the 16-carbonyl group
of VM
1 in the forward reaction, but in the reverse
reaction, it
should catalyze the formation of VM
1 from the
inactive 16
R-dihydroVM
1.
Therefore, it can be
argued that major role of the enzyme may
be in the biosynthesis of
VM
1, not in the self-defense against
the antibiotics
produced. To assess this possibility, the efficiency
of the enzyme in
the reverse reaction was measured with 16-dihydroVM
1 and
NADP
+. Two epimers of 16-dihydroVM
1
(16
R-epimer and 16
S-epimer) were
prepared by the
chemical reduction of VM
1 with NaBH
4, as
described
in Materials and Methods. With NADP
+
concentrations ranging from 0.2 to 20 mM and a
16-dihydroVM
1 concentration of 19 mM, only a trace amount
of VM
1 was produced
from the 16
R-epimer in the
presence of 20 mM NADP
+, but nothing was produced from the
16
S-epimer (data not shown).
Considering our detection limit
for VM
1, the forward reaction
producing
16
R-dihydroVM
1 was favored more than 910-fold
over the
reverse reaction producing VM
1, indicating that
under physiological
conditions, the enzyme should act in the
self-defense pathway
to inactivate VM
1.
 |
ACKNOWLEDGMENTS |
This study was supported, in part, by the Proposal-Based Advanced
Industrial Technology Development Organization (NEDO) of Japan, by the
Research for the Future Program of the Japan Society for the Promotion
of Science (JSPS), and by the Ministry of Agriculture, Forestry, and
Fisheries of Japan (BMP-97-V-4-1-b).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan. Phone: 81-6-879-7433. Fax:
81-6-879-7432. E-mail:
nihira{at}biochem.bio.eng.osaka-u.ac.jp.
 |
REFERENCES |
| 1.
|
Biot, A. M.
1984.
Virginiamycin: properties, biosynthesis, and fermentation, p. 695-720.
In
E. J. Vandamme (ed.), Biotechnology of industrial antibiotics. Marcel Dekker, Inc., New York, N.Y.
|
| 2.
|
Cocito, C.
1979.
Antibiotics of the virginiamycin family, inhibitors which contain synergistic compounds.
Microbiol. Rev.
43:145-198[Free Full Text].
|
| 3.
|
Delpierre, G. R.,
F. W. Eastwood,
G. E. Graeam,
D. G. I. Kingston,
P. S. Sarin,
L. Todd, and D. H. Williams.
1966.
Antibiotics of the ostreogrycin complex. Part II. Structure of ostreogrycin A2.
J. Chem. Soc.
1966:1653-1669.
|
| 4.
|
Hashimoto, K.,
T. Nihira, and Y. Yamada.
1992.
Distribution of virginiae butanolides and IM-2 in the genus Streptomyces.
J. Ferment. Bioeng.
73:61-65.
|
| 5.
|
Kim, H. S.,
T. Nihira,
H. Tada,
M. Yanagimoto, and Y. Yamada.
1989.
Identification of binding protein of virginiae butanolide C, an autoregulator in virginiamycin production, from Streptomyces virginiae.
J. Antibiot.
42:769-778[Medline].
|
| 6.
|
Kinoshita, H.,
H. Ipposhi,
S. Okamoto,
H. Nakano,
T. Nihira, and Y. Yamada.
1997.
Butyrolactone autoregulator receptor protein (BarA) as a transcriptional regulator in Streptomyces virginiae.
J. Bacteriol.
179:6986-6993[Abstract/Free Full Text].
|
| 7.
|
Kondo, K.,
Y. Higuchi,
S. Sakuda,
T. Nihira, and Y. Yamada.
1989.
New virginiae butanolides from Streptomyces virginiae.
J. Antibiot.
42:1873-1876[Medline].
|
| 8.
|
Lee, C.-K.,
M. Minami,
S. Sakuda,
T. Nihira, and Y. Yamada.
1996.
Stereospecific reduction of virginiamycin M1 as the virginiamycin resistance pathway in Streptomyces virginiae.
Antimicrob. Agents Chemother.
40:595-601[Abstract].
|
| 9.
|
Yamada, Y.,
K. Sugamura,
K. Kondo,
M. Yanagaimoto, and H. Okada.
1987.
The structure of inducing factors for virginiamycin production in Streptomyces virginiae.
J. Antibiot.
40:496-504[Medline].
|
| 10.
|
Yamada, Y.,
T. Nihira, and S. Sakuda.
1997.
Butyrolactone autoregulators, inducers of virginiamycin in Streptomyces virginiae: their structures, biosynthesis, receptor protein and induction of virginiamycin biosynthesis, p. 63-80.
In
W. R. Strohl (ed.), Biotechnology of antibiotics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
|
Antimicrobial Agents and Chemotherapy, November 1998, p. 2985-2988, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.